大脑粉样血管病变的临床管理
Aikaterini Theodorou1, Stella Fanouraki1, Eleni Bakola1
1Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Rimini 1, Chaidari, 12462 Athens, Greece.
Journal of clinical medicine
|June 26, 2025
概括
大脑粉样血管病变 (CAA) 是一种与衰老和阿尔茨海默病相关的渐进性脑疾病. 早期识别炎症亚型和正在进行的临床试验为改善这种具有挑战性的疾病的诊断和治疗提供了希望.
科学领域:
- 神经学 神经学
- 脑血管疾病 脑血管疾病
- 神经退行性疾病 神经退行性疾病
背景情况:
- 大脑粉样血管病变 (CAA) 是一种渐进的脑血管疾病.
- 它的特征在于,β-粉样蛋白在脑血管和脑膜血管壁中的积累.
- 患病率随着年龄的增长而增加,并且经常与阿尔茨海默病共存.
研究的目的:
- 调查CAA的临床表现. 研究CAA的临床表现.
- 审查诊断工具和治疗策略.
- 总结一些不常见的CAA亚型.
主要方法:
- 对CAA的临床表现,诊断和治疗的文献综述.
- 专注于偶发性,炎症性,遗传性和阳性形式.
- 分析当前的治疗挑战和正在进行的临床试验.
主要成果:
- CAA表现为脑内出血,短暂的神经发作或认知能力下降.
- 迅速治疗炎症性CAA可以改善结果.
- 遗传和阳性形式很少见,但越来越多地被认可.
- 缺乏有效的向疗法,但临床试验是有希望的.
结论:
- 需要更好地了解CAA的诊断和治疗.
- 早期识别和治疗炎症性CAA至关重要.
- 目前正在进行的研究为这种脑小血管疾病的未来治疗进展提供了希望.
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Aneurysm III: Interprofessional Care
30
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
30
Angle Closure Glaucoma: Treatment
708
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
708
Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
Open Angle Glaucoma: Treatment
591
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
591
Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42


